Table 1

Baseline characteristics

CharacteristicsEASE-2EASE-3
Empagliflozin 10 mg (N = 243)Empagliflozin 25 mg (N = 241)Placebo (N = 239)Empagliflozin 2.5 mg (N = 237)Empagliflozin 10 mg (N = 244)Empagliflozin 25 mg (N = 242)Placebo (N = 238)
Female125 (51.4)130 (53.9)130 (54.4)119 (50.2)130 (53.3)119 (49.2)124 (52.1)
Age, years45.7 ± 12.545.3 ± 13.944.5 ± 13.543.4 ± 14.242.4 ± 13.344.2 ± 13.542.2 ± 13.2
Race
 White230 (94.7)227 (94.2)225 (94.1)233 (98.3)232 (95.1)228 (94.2)223 (93.7)
 Black/African American6 (2.5)4 (1.7)8 (3.3)4 (1.7)10 (4.1)4 (1.7)5 (2.1)
 Asian6 (2.5)10 (4.1)8 (3.3)3 (1.3)2 (0.8)5 (2.1)2 (0.8)
 Other1 (0.4)0001 (0.4)5 (2.1)8 (3.4)
Region
 Europe131 (53.9)130 (53.9)133 (55.6)156 (65.8)148 (60.7)150 (62.0)148 (62.2)
 North America95 (39.1)94 (39.0)91 (38.1)60 (25.3)61 (25.0)60 (24.8)63 (26.5)
 Pacific12 (4.9)10 (4.1)10 (4.2)7 (3.0)12 (4.9)11 (4.5)5 (2.1)
 Latin America00012 (5.1)10 (4.1)14 (5.8)19 (8.0)
 Africa0002 (0.8)13 (5.3)7 (2.9)3 (1.3)
 Asia5 (2.1)7 (2.9)5 (2.1)0000
Diabetes duration, years22.8 ± 12.622.5 ± 13.022.4 ± 12.420.8 ± 11.920.5 ± 11.921.2 ± 11.421.7 ± 13.0
HbA1c, %8.10 ± 0.608.06 ± 0.538.13 ± 0.578.14 ± 0.618.19 ± 0.648.19 ± 0.658.19 ± 0.58
 <8.0%105 (43.2)109 (45.2)108 (45.2)101 (42.6)106 (43.4)98 (40.5)98 (41.2)
 ≥8.0%138 (56.8)132 (54.8)131 (54.8)136 (57.4)138 (56.6)144 (59.5)140 (58.8)
Weight, kg86.2 ± 18.285.6 ± 18.383.4 ± 16.781.6 ± 14.683.7 ± 17.083.3 ± 18.980.7 ± 16.9
BMI, kg/m2*29.5 ± 5.529.5 ± 6.028.5 ± 5.328.0 ± 4.428.7 ± 5.128.4 ± 5.627.8 ± 5.1
eGFR, mL/min/1.73 m295.0 ± 18.194.1 ± 18.995.9 ± 18.496.5 ± 19.997.3 ± 19.995.7 ± 19.797.8 ± 19.3
 ≥60236 (97.1)232 (96.3)232 (97.1)227 (95.8)234 (95.9)228 (94.2)230 (96.6)
 <607 (2.9)9 (3.7)7 (2.9)10 (4.2)10 (4.1)14 (5.8)8 (3.4)
Blood pressure, mmHg
 Systolic124.0 ± 15.5125.0 ± 14.9124.7 ± 15.7123.5 ± 14.6125.1 ± 15.1124.6 ± 15.0120.6 ± 14.8
 Diastolic75.8 ± 9.377.2 ± 9.275.6 ± 9.975.2 ± 8.976.9 ± 8.775.4 ± 9.274.7 ± 9.1
Total daily insulin dose, units/kg0.70 ± 0.240.74 ± 0.260.70 ± 0.230.70 ± 0.240.71 ± 0.240.71 ± 0.240.70 ± 0.24
Basal insulin dose0.36 ± 0.160.38 ± 0.170.37 ± 0.140.36 ± 0.140.37 ± 0.140.37 ± 0.150.36 ± 0.15
Bolus insulin dose0.34 ± 0.150.36 ± 0.170.35 ± 0.170.36 ± 0.170.35 ± 0.150.35 ± 0.150.35 ± 0.16
Type of insulin
 MDI144 (59.3)143 (59.3)142 (59.4)156 (65.8)162 (66.4)161 (66.5)157 (66.0)
 CSII99 (40.7)98 (40.7)97 (40.6)81 (34.2)82 (33.6)81 (33.5)81 (34.0)
  • Data are n (%) or means ± SD. The eGFR at baseline was estimated according to the Chronic Kidney Disease Epidemiology Collaboration equation. CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections.

  • *EASE-3: n = 236 for empagliflozin 2.5 mg.

  • †EASE-2: n = 230 for empagliflozin 10 mg, n = 226 for empagliflozin 25 mg, n = 226 for placebo; EASE-3: n = 224 for empagliflozin 2.5 mg, n = 221 for empagliflozin 10 mg, n = 226 for empagliflozin 25 mg, n = 223 for placebo.

  • ‡EASE-2: n = 184 for empagliflozin 10 mg, n = 186 for empagliflozin 25 mg, n = 172 for placebo; EASE-3: n = 192 for empagliflozin 2.5 mg, n = 190 for empagliflozin 10 mg, n = 189 for empagliflozin 25 mg, n = 187 for placebo.

  • ¶EASE-2: n = 186 for empagliflozin 10 mg, n = 187 for empagliflozin 25 mg, n = 170 for placebo; EASE-3: n = 189 for empagliflozin 2.5 mg, n = 190 for empagliflozin 10 mg, n = 187 for empagliflozin 25 mg, n = 187 for placebo.